Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$32.2 million.

  • C4 Therapeutics' Income from Continuing Operations fell 3040.62% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.1 million, marking a year-over-year decrease of 1287.62%. This contributed to the annual value of -$105.3 million for FY2024, which is 2051.2% up from last year.
  • C4 Therapeutics' Income from Continuing Operations amounted to -$32.2 million in Q3 2025, which was down 3040.62% from -$26.0 million recorded in Q2 2025.
  • C4 Therapeutics' Income from Continuing Operations' 5-year high stood at -$15.7 million during Q4 2021, with a 5-year trough of -$37.2 million in Q4 2022.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$27.0 million (2023), whereas its average is -$28.1 million.
  • Per our database at Business Quant, C4 Therapeutics' Income from Continuing Operations plummeted by 13748.24% in 2022 and then surged by 5068.2% in 2024.
  • C4 Therapeutics' Income from Continuing Operations (Quarter) stood at -$15.7 million in 2021, then tumbled by 137.48% to -$37.2 million in 2022, then increased by 6.54% to -$34.8 million in 2023, then rose by 0.52% to -$34.6 million in 2024, then grew by 6.96% to -$32.2 million in 2025.
  • Its Income from Continuing Operations stands at -$32.2 million for Q3 2025, versus -$26.0 million for Q2 2025 and -$26.3 million for Q1 2025.